Agios Pharmaceuticals AGIO Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's operating cash flow?
- Agios Pharmaceuticals (AGIO) reported operating cash flow of -$118.92M in Q1 2026.
- How has Agios Pharmaceuticals's operating cash flow changed year-over-year?
- Agios Pharmaceuticals's operating cash flow decreased by 6.7% year-over-year, from -$111.49M to -$118.92M.
- What is the long-term trend for Agios Pharmaceuticals's operating cash flow?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's operating cash flow has grown at a -2.2% compound annual growth rate (CAGR), from -$407.32M to -$372.98M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.